A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant

2024-05191-01
2024-11-20
2026-07-15
Klinisk läkemedelsprövning (CTR)
Janssen Cilag International
Godkänd
2024-10-29
Psychiatry and Psychology [F] - Mental Disorders [F03]
ProbarE i Lund AB, ProbarE i Stockholm AB, Affecta Psykiatrimottagnin, Region Oestergoetland, Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Region Stockholm – SLSO
Lund, Stockholm, Halmstad, Linkoping, Gothenburg, Stockholm
2024-511557-21-00
Therapeutic confirmatory (Phase III)

Forskningspersoner

20
Man, Kvinna
18-64